Company Profile
SCYNEXIS Stock Price, News & Analysis
- Ticker:
- SCYX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
5.20 USD (+0.78%)
Close
Last updated: August 6, 2026
50.6M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, SCYX closed up 0.78% at $5.20. No new same-company headline was identified in the current news window.
Company overview
Metabolic Kidney-Disease Lead Program
SCYNEXIS is developing SCY-770, an orally administered, selective direct activator of AMPK acquired as PXL-770. The program is being advanced for autosomal dominant polycystic kidney disease, where AMPK activation may address multiple drivers of disease progression.
Antifungal Franchise
SCY-247 is the company's second-generation fungerp antifungal. It is being developed in oral and intravenous formulations for patients with serious fungal infections, including those with limited treatment options.
Small-Molecule Development Model
The company combines internally developed anti-infective expertise with acquired clinical assets, concentrating resources on differentiated small molecules with potential applications in both rare disease and hospital-based care.
Future catalysts
Topline Phase 1 data for intravenous SCY-247 in the third quarter of 2026.
Initiation of a Phase 2 proof-of-concept study of SCY-770 in ADPKD in the fourth quarter of 2026.
Early efficacy data from the SCY-770 Phase 2 study in the second half of 2027.
Recent news
- 01
- 02
SCYNEXIS Announces One-for-Eight Reverse Stock Split
Source: SCYNEXIS
- 03
- 04
- 05
SCYNEXIS Announces $40.0 Million Private Placement
Source: SCYNEXIS
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of SCYNEXIS (SCYX)?
SCYNEXIS (SCYX) most recently closed at 5.20 USD, a +0.78% move versus the previous session.
What is the market cap of SCYNEXIS (SCYX)?
SCYNEXIS currently has a market capitalization of 50.6M USD on BioPharmSignal.
What does SCYNEXIS do?
Metabolic Kidney-Disease Lead Program SCYNEXIS is developing SCY-770, an orally administered, selective direct activator of AMPK acquired as PXL-770. The program is being advanced for autosomal dominant polycystic kidney disease, where AMPK activation may address multiple drivers of disease progression. Antifungal Franchise SCY-247 is the company's...
On which exchange is SCYX stock listed?
SCYNEXIS (SCYX) is associated with NASDAQ, United States, Biopharma.
What is SCY-770?
Initiation of a Phase 2 proof-of-concept study of SCY-770 in ADPKD in the fourth quarter of 2026.
Which conditions is SCYNEXIS targeting with SCY-770?
SCYNEXIS is associated with rare disease, metabolic disease based on its company overview and current catalyst commentary.
How does SCYNEXIS describe recent progress with SCY-770?
Initiation of a Phase 2 proof-of-concept study of SCY-770 in ADPKD in the fourth quarter of 2026.
What is PXL-770?
Metabolic Kidney-Disease Lead Program SCYNEXIS is developing SCY-770, an orally administered, selective direct activator of AMPK acquired as PXL-770.